LMAT (LeMaitre Vascular) ROCE %: 15.57% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LMAT LeMaitre Vascular Inc LMAT
100 GF Score
Price $81.45
GF Value $95.27
Valuation Modestly Undervalued
View Full Analysis

What is LeMaitre Vascular ROCE %?

LeMaitre Vascular LMAT +0.78% 100 ROCE % is 15.57% as of Jun. 2026. GuruFocus rates LMAT with a GF Score™ of 100/100 and a GF Value™ of $95.27 (Modestly Undervalued).

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. LeMaitre Vascular's annualized ROCE % for the quarter that ended in Jun. 2026 was 15.57%.

LeMaitre Vascular  (NAS:LMAT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

LeMaitre Vascular ROCE % Related Terms

LeMaitre Vascular ROCE % Historical Data

* Premium members only.

The historical data trend for LeMaitre Vascular's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LeMaitre Vascular ROCE % Chart

LeMaitre Vascular Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.64 9.89 13.11 13.62 14.60

LeMaitre Vascular Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.37 17.18 15.10 14.27 15.57
LMAT
100GF Score
LeMaitre Vascular Inc LMAT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LeMaitre Vascular ROCE % Calculation

LeMaitre Vascular's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=80.368/( ( (551.817 - 30.607) + (615.69 - 36.323) )/ 2 )
=80.368/( (521.21+579.367)/ 2 )
=80.368/550.2885
=14.60 %

LeMaitre Vascular's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=93.964/( ( (629.526 - 33.369) + (640.549 - 29.935) )/ 2 )
=93.964/( ( 596.157 + 610.614 )/ 2 )
=93.964/603.3855
=15.57 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 15.57% mean?
LeMaitre Vascular (LMAT) has a ROCE % of 15.57% as of Jun. 2026.
Is LeMaitre Vascular's ROCE % too high?
LeMaitre Vascular's current ROCE % is 15.57%. The Medical Devices & Instruments industry median ROCE % is 2.22. LeMaitre Vascular's value of 15.57% is 601.4% above this industry median. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's ROCE % compare to PLSE and XRAY?
LeMaitre Vascular's ROCE % of 15.57% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.22. LeMaitre Vascular's value of 15.57% is 601.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.22, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current ROCE % of 15.57% is 601.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current ROCE % is 15.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.27, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current ROCE % is 15.57% and 601.4% above the Medical Devices & Instruments industry median of 2.22. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current ROCE % is 15.57% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LeMaitre Vascular (LMAT) Overvalued in 2026?

Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued. The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.27. GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.

Key valuation signals for LMAT:

  • ROCE %: 15.57%
  • GF Value™: $95.27 vs. price of $81.45 (14.5% below fair value)
  • GF Score™: 100/100
  • Industry Position: 601.4% above the Medical Devices & Instruments median

No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LeMaitre Vascular Business Description

Other Exchanges LHU:Germany
Address 63 Second Avenue, Burlington, MA, USA, 01803
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score

Get the complete analysis for LMAT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$81.45
Price
$95.27
GF Value